Lipid assay improves cardiovascular risk prediction: Jeff Meeusen, Ph.D.
About this episode
Jeff Meeusen, Ph.D., explains how Mayo Clinic Laboratories' new MI-Heart Ceramides assay helps guide the management of patients with mildly to moderately high cholesterol. The test measures levels of lipids beyond cholesterol that boost cardiovascular risk.
Show notes
(00:31)
Could you provide us a little bit about your background?
(01:20)
Could you give us a brief overview of this assay?
(02:45)
What patients should have this test and when should it be performed?
(04:25)
Could you talk a little bit about alternative test options and how they compare to our ceramides test?
(05:58)
Can you go a little bit further into how these results can impact patient care and how you may monitor patients in the future with this testing?
Get every episode summarized
Each time Answers from the Lab publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Answers from the Lab
Unique Assays Advance Care of Complex Autoimmune Skin Conditions
Answers from the Lab
Digital Advances: What’s Next for Clinical Diagnostics?
Answers from the Lab
Preeclampsia Test Helps Extend Pregnancy to Improve Outcomes
Answers from the Lab
Breakthrough Test Enhances Peripheral Neuropathy Care and Research
Answers from the Lab